{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-24-000003","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.742628+00:00","generated_at":"2026-06-07T02:42:12.232996+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Apyx Medical reports preliminary Q4 rev $14.2-14.6M (+13-16% YoY); FY rev $51.9-52.3M (+17-18%)","bullets":["Total Q4 revenue $14.2-14.6M, growth 13-16% YoY; Advanced Energy $11.9-12.3M (+12-16%).","Full year total revenue $51.9-52.3M (+17-18%); Advanced Energy $43.1-43.5M (+17-18%); OEM $8.8M (+14%).","CEO says sales softer than expected due to challenging macro environment in cosmetic surgery market; slower new customer adoption.","Company plans to release full Q4 and FY 2023 results in March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-24-000003","json":"https://secwatch.observer/filing/0000719135-24-000003.json","markdown":"https://secwatch.observer/filing/0000719135-24-000003.md","text":"https://secwatch.observer/filing/0000719135-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000003/0000719135-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000003/apyx-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:42:12.232996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64e4426d4d458ef1d55088be2bab3c2f9f1289d6","claim":"Apyx Medical Corp reported the fourth quarter ended December 31, 2023 results: revenue $14.2 to $14.6 million.","evidence_excerpt":"Total revenue in a range of $14.2 to $14.6 million, representing growth of 13% to 16% year-over-year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000003/0000719135-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$14.2 to $14.6 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"73b9e45705a1aef98bdf9ae7f554127a603d53be","claim":"Apyx Medical Corp reported the year ended December 31, 2023 results: revenue $51.9 to $52.3 million.","evidence_excerpt":"Total revenue in a range of $51.9 to $52.3 million, representing growth of 17% to 18% year-over-year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000003/0000719135-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$51.9 to $52.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}